Therapy of Nonnecrotizing Anterior Scleritis with Subconjunctival Corticosteroid Injection

Elmer Y. Tu, William W. Culbertson, Stephen C. Pflugfelder, Andrew Huang, James C. Chodosh

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%) responded poorly. Nine patients (45%) required no further therapy. Average symptom- free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and/or perforation and should be considered as adjunctive therapy in localized disease.

Original languageEnglish (US)
Pages (from-to)718-724
Number of pages7
Issue number5
StatePublished - 1995

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Therapy of Nonnecrotizing Anterior Scleritis with Subconjunctival Corticosteroid Injection'. Together they form a unique fingerprint.

Cite this